Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Constantin Schmidt

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Frontiers in Immunology|July 20, 2023
IRF4 is required for migration of CD4<sup>+</sup> T cells to the intestine but not for Th2 and Th17 cell maintenanceConstantin Schmidt, Aenne Harberts, Daniel Reimers, et al.
BMC Cancer|November 23, 2020
Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtypeJenny Krause, Johann von Felden, Christian Casar, et al.
Journal of Hepatology|January 15, 2019
Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitisTobias Schmidt, Dorothee Schwinge, Tim Rolvien, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 27, 2022
Kidney-resident innate-like memory γδ T cells control chronic <i>Staphylococcus aureus</i> infection of miceTabea Bertram, Daniel Reimers, Niels C Lory, et al.
Annals of Hepatology|August 15, 2024
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinomaLouisa Stern, Constantin Schmidt, Lorenz Kocheise, et al.
Frontiers in Immunology|February 8, 2024
Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver diseaseLorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.
Frontiers in Immunology|January 25, 2024
PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver diseaseLorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.
Annals of Hepatology|October 13, 2025
Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumabLorenz Kocheise, Jan Kempski, Yunhe Tang, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 8, 2024
Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapyJoao Gorgulho, Sven H Loosen, Ramsha Masood, et al.
Science Immunology|August 10, 2020
Pathogen-induced tissue-resident memory T<sub>H</sub>17 (T<sub>RM</sub>17) cells amplify autoimmune kidney diseaseChristian F Krebs, Daniel Reimers, Yu Zhao, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Frontiers in Immunology|July 20, 2023
IRF4 is required for migration of CD4<sup>+</sup> T cells to the intestine but not for Th2 and Th17 cell maintenanceConstantin Schmidt, Aenne Harberts, Daniel Reimers, et al.
BMC Cancer|November 23, 2020
Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtypeJenny Krause, Johann von Felden, Christian Casar, et al.
Journal of Hepatology|January 15, 2019
Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitisTobias Schmidt, Dorothee Schwinge, Tim Rolvien, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 27, 2022
Kidney-resident innate-like memory γδ T cells control chronic <i>Staphylococcus aureus</i> infection of miceTabea Bertram, Daniel Reimers, Niels C Lory, et al.
Annals of Hepatology|August 15, 2024
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinomaLouisa Stern, Constantin Schmidt, Lorenz Kocheise, et al.
Frontiers in Immunology|February 8, 2024
Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver diseaseLorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.
Frontiers in Immunology|January 25, 2024
PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver diseaseLorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.
Annals of Hepatology|October 13, 2025
Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumabLorenz Kocheise, Jan Kempski, Yunhe Tang, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 8, 2024
Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapyJoao Gorgulho, Sven H Loosen, Ramsha Masood, et al.
Science Immunology|August 10, 2020
Pathogen-induced tissue-resident memory T<sub>H</sub>17 (T<sub>RM</sub>17) cells amplify autoimmune kidney diseaseChristian F Krebs, Daniel Reimers, Yu Zhao, et al.
Pageof 3